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ABSTRACT
Background
Age-related macular degeneration (AMD) is the major cause of blindness in the elderly. Those
with the neovascular end-stage of disease have irreversible loss of central vision. AMD is a
complex disorder in which genetic and environmental factors play a role. Polymorphisms in the
complement factor H (CFH) gene, LOC387715, and the HTRA1 promoter are strongly associated
with AMD. Smoking also contributes to the etiology. We aimed to provide a model of disease
risk based on these factors.
Methods and Findings
We genotyped polymorphisms in CFH and LOC387715/HTRA1 in a case–control study of 401
patients with neovascular AMD and 266 controls without signs of disease, and used the data to
produce genetic risk scores for the European-descent population based on haplotypes at these
loci and smoking history. CFH and LOC387715/HTRA1 haplotypes and smoking status exerted
large effects on AMD susceptibility, enabling risk scores to be generated with appropriate
weighting of these three factors. Five common haplotypes of CFH conferred a range of odds
ratios (ORs) per copy from 1 to 4.17. Most of the effect of LOC387715/HTRA1 was mediated
through one detrimental haplotype (carriage of one copy: OR 2.83; 95% confidence interval [CI]
1.91–4.20), with homozygotes being at particularly high risk (OR 32.83; 95% CI 12.53–86.07).
Patients with neovascular macular degeneration had considerably higher scores than those
without disease, and risk of blinding AMD rose to 15.5% in the tenth of the population with
highest predicted risk.
Conclusions
An individual’s risk of developing AMD in old age can be predicted by combining haplotype
data with smoking status. Until there is effective treatment for AMD, encouragement to avoid
smoking in those at high genetic risk may be the best option. We estimate that total absence of
smoking would have reduced the prevalence of severe AMD by 33%. Unless smoking habits
change or preventative treatment becomes available, the prevalence of AMD will rise as a
consequence of the increasing longevity of the population.
The Editors’ Summary of this article follows the references.
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Age-related macular degeneration (AMD) is the most
common cause of visual disability in the elderly, and is
increasing in prevalence in the Western world as the
population ages. In addition to age and smoking, genetic
factors play a major role in susceptibility to AMD. There is
higher concordance in monozygotic than in dizygotic twins
[1], and although there is rarely clear Mendelian inheritance,
cases tend to cluster in families [2,3]. The search for
susceptibility genes has been performed using linkage studies
in AMD families, followed by family-based and case-control
association studies. Chromosome 1q31 was ﬁrst implicated in
a linkage study involving a large family [4], and the same
region was supported consistently in several genome-wide
scans based on analysis of smaller multiplex families [5–13].
Several polymorphisms in CFH, the gene encoding comple-
ment factor H, were found to be strongly associated with
AMD, and single nucleotide polymorphism (SNP) rs1061170,
encoding a nonsynonymous change from tyrosine to histidine
at codon 402, was proposed as the main determinant of
disease [14–18]. CFH and the closely related genes CFHR3,
CFHR1, CFHR4, CFHR2, and CFHR5 are arranged in tandem
at the proximal end of a cluster of genes involved in
regulation of complement activation. Recently we examined
this gene cluster in detail and identiﬁed a large deletion that
removed both CFHR3 and CFHR1 on a strongly protective
haplotype [19].The inhibitory activity of complement factor
H is controlled by binding of C-reactive protein (CRP), which
increases afﬁnity for C3b and leads to down-regulation of
complement activity [20]. There are no known coding
polymorphisms in the small CRP gene, but plasma CRP levels
are determined by SNPs within its promoter region [21]. Of
most signiﬁcance in persons of European descent is the
triallelic (A/C/T) SNP rs3091244, of which the C allele results
in lowest plasma CRP levels and the T allele the highest.
Many previous genome-wide scans also support linkage to
Chromosome 10q26, with this region showing the strongest
association on meta-analysis [13]. Two reports implicated
either LOC387715 or PLEKHA1 as a major contributor to
AMD susceptibility [22,23], and recently HTRA1 (which lies 4
kb distal to LOC387715) emerged as a leading contender for
the second AMD susceptibility gene [24,25]. HTRA1 encodes a
serine protease that is expressed in the retina; however, the
mechanism of action of the LOC387715 gene product remains
to be elucidated. The common c.205G.T nonsynonymous
coding SNP (rs10490924), which changes alanine to serine at
codon 69 of LOC387715, is in close linkage disequilibrium
(LD) with rs11200638 in the promoter of HTRA1, which may
regulate its expression [25].
Although earlier studies gave conﬂicting results, the large
Beaver Dam Eye Study in 1993 showed that cigarette smoking
increases the risk of exudative (or neovascular) macular
degeneration [26]. Other sizeable studies have since con-
ﬁrmed that smoking is a risk factor in all forms of AMD [27–
29].
In contrast to most previous studies, which assessed AMD
cases ranging from early to late stages of disease, we restricted
our cases to those with the blinding neovascular form of AMD
in one or both eyes, and compared them to controls with no
sign of macular disease. We aimed to reﬁne the association of
CFH and LOC387715/HTRA1 with neovascular AMD and to
form a model of AMD risk based on inherited variation in
these genes in conjunction with smoking status.
Methods
Study Population and Diagnostic Criteria
Cases (n ¼ 401) with choroidal neovascularisation due to
AMD in at least one eye were recruited from ophthalmology
clinics in the Royal Victoria Hospital, Belfast, UK, which is
the regional referral centre for Northern Ireland. Cases were
recruited opportunistically during two intervals, the ﬁrst
between June 2002 and August 2003 (n¼305) and the second
between June and September 2006 (n ¼ 96). Of those invited
to participate, 98% agreed. Prior to approaching potential
participants, the diagnosis of neovascular AMD was con-
ﬁrmed by clinical examination followed by ﬂuorescein
angiography. A control group (n¼266) was recruited through
random sampling of older adults (aged 65 y and above) from a
population-based register, with no exclusion criteria. In this
sample the participation rate was ;50%; those who refused
to participate were more likely to be older and female.
Stereoscopic digital fundus photographs were captured at
the time of examination, and images were sent to the
photographic reading centre for grading using the deﬁnitions
of the Wisconsin Age Related Maculopathy Grading System.
Fundi of controls were free of any drusen, or had fewer than
ﬁve hard drusen of diameter less than 63 microns. They had
no focal pigmentary irregularities (i.e., hyperpigmentation or
hypopigmentation). All participants were from Northern
Ireland and described themselves as of European descent.
Current smoking status and smoking history were obtained
through the use of a questionnaire previously validated in the
Whitehall study, with participants classiﬁed into never
smokers, ex-smokers or current smokers [30]. Smoking
prevalence data for the UK population in 1974 and 2003
were obtained from the General Household Survey [31], UK
Ofﬁce for National Statistics.
Informed written consent was obtained from all subjects
involved (Text S1). Our study was approved by the Research
Ethics Committee of the Queen’s University of Belfast (Text
S2).
Genotyping
DNA was extracted from peripheral blood leucocytes or
frozen buffy coat samples using standard protocols. High-
throughput SNP genotyping was outsourced and based on
Illumina bead technology (Illumina, San Diego, United
States), supplemented in-house with multiplex PCR and
primer extension methodology (ABI Snapshot). Rs11200638
was typed by sequencing. All primer sequences are available
from AEH. Genotype data were entered in linkage format
into Haploview [32] for automated analysis of CFH and
LOC387715 haplotypes. Scoring risk at the CFH-related
cluster was based on haplotypes of SNPs rs6677604,
rs3753396, rs419137, and rs2284664. Nonsynonymous coding
SNPs rs1061170 (Y402H) and rs800292 (I62V) were also typed.
The three SNPs typed within LOC387715 (rs10490923,
rs2736911, and rs10490924) tagged four common haplotypes
of a haplotype block that extended across LOC387715 to the
promoter of HTRA1. Genotyping of CRP markers rs3091244
and rs1205 was restricted to a subgroup of 170 cases and 170
controls, and four CRP haplotypes were assessed. All markers
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with D9 ¼ 1, therefore haplotypes could be assigned with
conﬁdence. LOC387715/HTRA1 haplotypes consisted of
rs10490924 and rs11200638 (D9 ¼ 0.98; r
2 ¼ 0.93), and were
assigned using PHASE [33].
Statistical Analysis
The statistical analyses and model building were pre-
planned before collection of genotype data. Allele frequency
differences in cases and controls were assessed by performing
Pearson’s Chi-square test of association. Each CFH haplotype
was entered into the logistic regression model as a count (0, 1,
or 2) depending on the number of copies of the haplotype an
individual carried. To avoid collinearity problems the lowest
risk haplotype was omitted from the model so that odds ratios
(ORs) were measured relative to homozygote carriers of this
haplotype. An exception to this approach was made for
analysis of the LOC387715 and LOC387715/HTRA1 region
where increased risk of AMD was conﬁned to one haplotype,
with a much higher risk in homozygote carriers than
predicted by the multiplicative model. For our ﬁnal risk
analysis, the number of copies carried of this detrimental
haplotype were coded 0, 1, or 2. Tests for deviation from the
multiplicative genetic model and for interactions between
genetic risk factors and smoking were obtained using
likelihood ratio Chi-squared tests. The ﬁtted logistic model
produced ORs that were converted to predicted probabilities
of AMD for each possible combination of CFH and
LOC387715/HTRA1 haplotypes and smoking status. Conver-
sion was performed using an estimated prevalence of severe
AMD of 3% and known frequencies for haplotypes and
smoking status, and by assuming that CFH, LOC387715/
HTRA1, and smoking were independently distributed in the
UK population. These predicted probabilities were used to
sort the combinations in order of increasing predicted AMD
risk and then to divide the population into approximate
tenths of predicted AMD risk. More detailed statistical
information is provided in Table S1.
Results
Participant Population
Our study involved 401 patients with end-stage neovascular
AMD in at least one eye and 266 age-matched controls with
healthy fundi. There was a slight preponderance of females in
each group, as expected for this age group (Table S2). Mean
age at examination was in the mid-seventies for each group
(cases 75.6 years; controls 75.8 years), with individuals ranging
in age from 54 to 98 y in the case group and from 66 to 100 y
in the control group.
The CFH Region Associates with AMD
Our analysis of the haplotype structure of CFH, CFHR3, and
CFHR1hasbeenreportedelsewhere[19]andwassupportedby
ﬁnal HapMap data [34]. There was complete LD within each
block, and a strong spine of LD between the three large
haplotype blocks covering these genes (multiallelic D9 ¼ 0.89
between blocks 1 and 2, and 0.91 between blocks 2 and 3). We
typed the ﬁve common haplotypes of the second block, which
encompassedexon11totheendofintron17ofCFH,taggedby
SNPs rs6677604, rs3753396, rs419137, and rs2284664. Three
haplotypes (1:GACG, 2:GAAG, and 3:GGAG) were associated
with increased risk and two (4:GAAA and 5:AAAG) were
protective of AMD. The most protective (haplotype 5) was
associated with deletion of CFHR3 and CFHR1 from block 3.
The LOC387715/HTRA1 Region Associates with AMD
The extremely strong association of LOC387715 on
Chromosome 10 with AMD was conﬁrmed by genotyping
SNPs rs10490923, rs2736911, and rs10490924. These SNPs
were in complete LD and four haplotypes were identiﬁed. Of
most importance was rs10490924, with the risk allele (T)
being found only on haplotype 2, and present on 48.9% of
AMD and 20.5% of control chromosomes. SNP rs11200638 in
the promoter of HTRA1 was typed and found to be in
extremely high LD (D9 ¼ 0.98; r
2 ¼ 0.93) with rs10490924 and
with LOC387715 haplotypes, with the risk allele (A; 47.9% of
AMD and 19.4% of control chromosomes) closely associated
with rs10490924 allele T and LOC387715 haplotype 2 (Table
S2). All four possible haplotypes of LOC387715/HTRA1 that
combined rs10490924 and rs11200638 were found (1:GG,
2:TA, 3:TG, 4:GA), although haplotypes 3 and 4 were
exceedingly rare, totalling 1.6% of all chromosomes. These
rare haplotypes were distributed similarly through cases and
controls and were merged with haplotype 1 for all further
analyses. Based on simple counts of alleles or haplotypes, the
LOC387715/HTRA1 haplotype provided marginally better
predictive value than either of the constituent SNPs
individually (Table S3). The detrimental LOC387715/HTRA1
haplotype 2 was present on 47.0% of AMD and 18.2% of
control chromosomes. Haplotype data for CFH and
LOC387715/HTRA1 and smoking status of our cases and
controls are shown in Table S4.
No Association of CRP with AMD
The triallelic SNP rs3091244 within the promoter of the
CRP gene (which affects plasma levels of CRP) was typed, and
rs1205 was also assessed to increase haplotype informative-
ness for this gene. Four haplotypes were identiﬁed. The rarest
haplotype (4:AC, associated with high CRP plasma level [21])
was more prevalent in cases; however, the overall haplotype
distribution in cases and controls failed to reach statistical
signiﬁcance (p ¼ 0.06), and using conventional logistic
regression the weak association was attenuated by adjustment
for carriage of LOC387715 haplotype 2 and smoking. There
was only weak and nonsigniﬁcant evidence of interaction
between CFH haplotype and CRP genotype.
Association with Smoking
As expected, smoking (p , 0.001) and previous history of
smoking (p ¼ 0.05) were associated with disease status,
independent of CFH and LOC387715 haplotype. There was
no evidence of interaction between smoking and LOC387715/
HTRA1 haplotype (p ¼ 0.42), or between smoking and CFH
haplotype (p¼0.07), or between CFH and LOC387715/HTRA1
haplotypes (p ¼ 0.42). Smoking history in the controls
correlated closely with the data from the UK General
Household Survey with 54% and 55% never smokers,
respectively; however, this group contained slightly fewer
smokers (12% versus 17%) and more ex-smokers than in the
general population.
Logistic Regression Analyses
Logistic regression analysis was performed to examine the
effect of the CFH and LOC387715/HTRA1 haplotypes carried
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conferred the lowest risk, with haplotype 4 also being
protective. Haplotype 2 remained the most detrimental, with
carriage increasing the risk of AMD more than 4-fold relative
to haplotype 5 (Table 1). Two nonsynonymous coding SNPs,
rs1061170 (Y402H) and rs800292 (I62V), located within block
1o fCFH [19], were also typed. CFH block 2 haplotypes 1 and 2
were strongly associated with the high-risk allele C of
rs1061170 (402H), with the T allele associated with haplotypes
3, 4, and 5. The low-risk A allele of rs800292 (I62) was
associated uniquely with haplotype 4. The detrimental effect
of variation at LOC387715/HTRA1 on AMD phenotype was
mediated through haplotype 2. Unlike CFH, there was not a
multiplicative effect with carriage of two LOC387715/HTRA1
risk haplotypes. A single copy of haplotype 2 increased the
risk of AMD nearly 3-fold relative to the haplotype 1 baseline
(Table 2); however, homozygotes for haplotype 2 had their
risk greatly elevated by a factor of 33. Past and present
smokers showed a graded increase in risk of AMD compared
to those who had never smoked (Table 3).
AMD Risk Scoring System
A simple multifactorial AMD risk-scoring system for each
individual was developed by multiplying the ORs for genetic
effects of each carried haplotype of CFH and LOC387715/
HTRA1, and smoking status.
The overall theoretical distribution of risk for the Euro-
pean-descent population was estimated from haplotype
frequencies (derived from reported frequency data available
from large studies for the polymorphisms that constituted
each haplotype, which did not differ signiﬁcantly from
frequencies found in our control group) combined with UK
smoking data since 1974, which classiﬁed 55% of our present-
aged population as never smokers, 28% as ex-smokers, and
17% as current smokers. This population distribution was
split by deciles into ten risk groups for further analysis.
As expected, our controls with no sign of macular disease
were biased marginally (and nonsigniﬁcantly) in the super-
normal direction, with slight clustering in the lower-risk
groups, whereas our AMD cases fell predominantly into high-
risk groups (Figure 1). The risk of developing end-stage AMD
in at least one eye in advancing years can be predicted from
an individual’s risk score (Figure 2). Those with scores falling
within the lowest-risk groups have minimal risk of developing
AMD. The overall population prevalence of 3% was exceeded
only in the two highest-risk groups, and AMD risk rose steeply
to 15.5% for those in the highest tenth of the population.
Overall, genetic factors contributed more than smoking
status to risk of AMD, with LOC387715/HTRA1 proving more
inﬂuential than CFH. The smoking element of the AMD risk
score was elevated in our cases compared to controls. Age of
onset of neovascular disease in the ﬁrst eye was known for 296
of the AMD cases. Those who smoked showed earlier onset of
end-stage disease than did former or nonsmokers (Figure 3; F
¼ 9.81, degrees of freedom ¼ 2,284; p   0.001). There was a
similar signiﬁcant trend to earlier onset with increasing risk
group (F ¼ 11.97, degrees of freedom ¼ 1,277; p   0.001).
When AMD patients were separated into two equal groups
based on age of end-stage disease in the ﬁrst eye, there was an
increased effect from CFH and smoking in the earlier-onset
group and of LOC387715/HTRA1 in the later-onset group
(unpublished data).
Discussion
Our study assessed the inﬂuence of genes in the CFH and
LOC387715/HTRA1 regions and smoking status on the
etiology of neovascular AMD. We developed a risk model
for disease based on comprehensive haplotyping of the genes
followed by analysis using logistic regression that also
included smoking status. Our model is the ﬁrst that we know
of to take account of haplotypes within the CFH and
LOC387715/HTRA1 regions, and allows early identiﬁcation
of those at high risk of developing neovascular AMD in old
age. AMD was not inevitable for those in the highest-risk
categories, hence exposure to a trigger may be necessary for
development of disease.
AMD is one of the most common multifactorial diseases of
the elderly. For several years, genes have been thought to play
a role in susceptibility. The model generally applied to such
complex disorders has been of multiple genes each contri-
buting a small effect to overall risk, in conjunction with
environmental factors. This model has been further compli-
cated by the possibility of genes acting with either dominant
or negative effects, of gene–gene or gene–environment
interactions, and of genetic heterogeneity in which mutations
in different genes may have a major inﬂuence in different
individuals. As is often the case in clinical genetics, a much
more straightforward pattern emerges when the possibilities
are investigated and some ruled out. Credit must be given to
Table 1. Effect of Haplotype Variation in CFH on AMD by
Simultaneous Logistic Regression Analysis Including LOC387715/
HTRA1 and Smoking Status
CFH
Haplotype
Population
Frequency
a
Odds
Ratio
b
1 (GACG) 0.14 3.07 (95% CI 1.82–5.16)
2 (GAAG) 0.35 4.17 (95% CI 2.61–6.64)
3 (GGAG) 0.15 2.82 (95% CI 1.71–4.63)
4 (GAAA) 0.17 1.76 (95% CI 1.05–2.95)
5 (AAAG) 0.19 1.00
aFrequencies were derived from Eupropean-descent population data.
bOdds ratios relate to the most protective factor (shown in bold) and may be interpreted
as the increase in risk of AMD per copy of the haplotype carried.
doi:10.1371/journal.pmed.0040355.t001
Table 2. Effect of Haplotype Variation in LOC387715/HTRA1 on
AMD by Simultaneous Logistic Regression Analysis Including
CFH and Smoking Status
LOC387715/HTRA1
Haplotype 2 (TA)
Population
Frequency
a
Odds
Ratio
b
2 copies 0.04 32.83 (95% CI 12.53–86.07)
1 copy 0.32 2.83 (95% CI 1.91–4.20)
0 copies 0.64 1.00
aFrequencies were derived from European-descent population data.
bOdds ratios relate to the most protective factor (shown in bold) and may be interpreted
as the increase in risk of AMD per copy of the haplotype carried.
doi:10.1371/journal.pmed.0040355.t002
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studies of families with more than one affected patient from
which AMD susceptibility loci have been identiﬁed. Although
individual studies often identiﬁed linkages that have not been
conﬁrmed, meta-analyses [13] clearly revealed the regions of
Chromosomes 1 and 10 (from which the CFH gene cluster and
LOC387715/PLEKHA1/HTRA1 have recently emerged) as
major susceptibility loci for all forms of AMD. It is
increasingly likely that the genetic component of AMD
should be viewed as oligogenic rather than polygenic.
The CFH gene cluster comprises ﬁve related genes that are
all expressed. These genes share a very high level of homology
arising from gene duplication, and care must be taken in
typing and identifying polymorphic variants at the C-
terminal region of CFH and in the CFH-related genes. We
chose to score risk on the basis of ﬁve haplotypes of the most
central block, which was in strong LD with the adjacent
haplotype blocks in CFH, CFHR3, and CFHR1. Our earlier
studies showed strong association between AMD and markers
extending across this region [19]. Any coding variants or
polymorphisms regulating splicing or expression of these
genes may affect risk, and may be based within different
haplotype blocks. We also typed Y402H and I62V, but analysis
of these common coding polymorphisms did not confer
additional information affecting AMD risk. Other studies
have limited their analysis to the effect of Y402H, which has
been regarded as the main determinant of disease, but this
analysis gives an incomplete and inaccurate representation of
the region. Only haplotype analysis can assess the effect of
combinations of all the coding variants in CFH that may
contribute to AMD susceptibility. The C allele of rs1061170,
which types histidine at codon 402 within the ﬁrst haplotype
block, is associated with a haplotype conferring high risk of
AMD, and is coupled with our haplotypes 1 and 2 in the
second haplotype block. It is also in complete LD with several
other SNPs, one of which has the potential to create a novel
splice site and to introduce a new exon containing a
premature stop codon. This variant would be expected to
result in nonsense-mediated decay of the transcript and
reduced CFH levels. Despite being associated with the T allele
of rs1061170, haplotype 3 is only marginally less severe in risk
than haplotype 1. Haplotypes 4 and 5 are relatively
protective. We previously identiﬁed a deletion of 85 kb
encompassing CFHR1 and CFHR3, which plausibly confers
the protective effect of haplotype 5 [19]. The coding variant
most strongly associated with haplotype 4 may be the A allele
of rs800292, which encodes I62, though this represents a
conservative amino acid change. Further work is needed to
clarify the molecular bases of the haplotypic effects.
Much interest surrounds the identity of the AMD suscept-
ibility locus on Chromosome 10. Very strong data focus on
the protein encoded by the hypothetical gene LOC387715,
with the alanine-to-serine polymorphism detected by
rs10490924 as the most probable causative variant [23].
Alternatives are either PLEKHA1 or HTRA1, which ﬂank
the locus; HTRA1, which encodes a serine protease, is the
more attractive on functional grounds. Another possibility is
that the putative exons of LOC387715 or additional open
reading frames in the HTRA1 promoter region may be
included in alternative transcripts of HTRA1. The LOC387715
transcript is exceedingly rare, but has been reported to be
present at very low levels in the retina [23]. The markers we
typed for this locus identiﬁed all common haplotypes of a
block that encompassed LOC387715 to the HTRA1 promoter.
In contrast to the CFH gene cluster, the effect of the
LOC387715/HTRA1 region on AMD susceptibility appeared
to be mediated through a single detrimental haplotype, with
all others being generally protective. In addition to carrying
the rare coding variant of rs10490924, the detrimental
haplotype was also very strongly associated with several
variants in the untranslated region of LOC387715 and in the
promoter of HTRA1, and we cannot at present discriminate
between the relative merits of variation in LOC387715 or the
HTRA1 promoter as effectors of AMD susceptibility at this
locus.
Further genetic or environmental factors, or their inter-
actions, may be found to affect AMD risk. These factors
should be assessed for effect using a regression model that
includes all proven genetic and environmental factors, rather
than in isolation. Initial reports are prone to inﬂation to
some extent by type 1 error. Conﬂicting data have been
reported about a possible interaction between LOC387715
and smoking [35,36]. Our evidence does not support an
interaction, and we ﬁnd limited support for an interaction
recently reported between CFH and CRP [37]. Interaction
between CFH and the genes encoding complement C2 or
complement factor B [38], and CFH and an excision repair
gene named ERCC6 [39] await conﬁrmation.
Options for reducing the future burden of AMD appear as
our knowledge increases. Although smoking status is of less
importance than the two main genetic factors, it is a relatively
Figure 1. Distribution of AMD Cases and Controls According to Predicted
Risk Group Estimated for UK Persons of European Descent
The percentages of AMD cases and controls within each risk group are
shown.
doi:10.1371/journal.pmed.0040355.g001
Table 3. Effect of Smoking Status on AMD by Simultaneous
Logistic Regression Analysis Including CFH and LOC387715/
HTRA1
Smoking Status Population Frequency Odds Ratio
Smoker 0.17 3.14 (95% CI 1.82–5.42)
Ex-smoker 0.28 1.46 (95% CI 0.96–2.22)
Never smoker 0.55 1.00
doi:10.1371/journal.pmed.0040355.t003
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load. Our data show that if none of our population had
smoked, there would have been an overall reduction of 33%
in AMD today. Our current and ex-smokers lost vision at an
earlier age, so it is probable that our calculations under-
estimate the beneﬁt to the population from nonsmoking. We
did not assess the importance of smoking on earlier stages of
AMD; however, delaying either onset of disease or advance-
ment to the blinding end-stage by 5–10 y would have a major
impact on prevalence of blindness. It is now possible to
identify those at high genetic risk for whom smoking is
particularly unwise. In the past, smokers have been prepared
to ignore greatly increased risks of lung cancer and other
smoking-related diseases, but attitudes to smoking are
changing. Relatives of AMD patients are more likely to carry
an excess of LOC387715/HTRA1 and CFH-related genetic risk
factors. Those who are shown to be at high risk, with relatives
who have lost their vision, may be more prepared to heed
advice to refrain from smoking than the general population.
Gene therapy to repair genetic defects is still in the
experimental phase and is largely unproven. Of great promise
are methods aimed at gene silencing by degradation of RNA
using short interfering double-stranded RNA molecules.
Deletion of CFHR1 and CFHR3 from the CFH-related gene
cluster is strongly protective against AMD, hence these genes
make excellent targets for silencing in future studies aimed at
reducing the burden of disease.
Study Limitations
We assessed the genetic factors and smoking history, which
are generally accepted as conferring high population-
attributable risk for AMD. The model we developed to
estimate risk of neovascular AMD best ﬁts our data, and it is
important that it should be validated in independent datasets
of similar phenotypes. It is possible that rare variants in other
genes may be found to be highly inﬂuential in a small
proportion of the population, and may cause AMD in a few
individuals predicted to be at low risk using our present
model. Genes with a modifying effect on AMD risk may also
be identiﬁed. In either case, our model for prediction of AMD
risk may be modiﬁed easily. CFH may also affect risk of
myocardial infarction [40], and we made no attempt to adjust
for this condition or for smoking-related diseases that affect
longevity.
Supporting Information
Table S1. Supplementary Statistical Data
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Background. Age-related macular degeneration (AMD) is the leading
cause of vision loss in the elderly. The macula is the central region of the
retina, the tissue at the back of the eye that converts light into electrical
messages and sends them to the brain. In the commonest form of
AMD—‘‘dry’’ AMD—the light-sensitive cells in the macula gradually die.
In ‘‘wet’’ or ‘‘neovascular’’ AMD (one in 10 cases of AMD, but
responsible for 90% of severe AMD-related blindness), abnormal blood
vessels grow below the macula. Fluid leaking out of these vessels
dislodges and damages the macula, after which loss of vision occurs
rapidly. Both forms of AMD destroy the sharp central vision that is
needed for reading and driving, leaving only dim, blurred images or a
black hole at the center of vision. Neither form can be cured but with
wet AMD the loss of vision can sometimes be slowed or halted if caught
early by destroying the new blood vessels with laser surgery or a
technique called photodynamic therapy or by blocking their formation
by injecting special drugs into the eye.
Why Was This Study Done? No-one knows what causes AMD but
factors that increase a person’s risk of developing the disease include
increasing age, smoking, being white, and a family history of AMD.
Recently, researchers have identified several ‘‘polymorphisms’’ (inherited
DNA sequence variations that are common within populations) that are
associated with AMD. These polymorphisms are in the complement
factor H gene (the scientific symbol for this gene is CFH) and in a gene
region called LOC387715/HTRA1. It would be useful to be able to use
these risk factors to identify those people at the highest risk of
developing neovascular AMD before the disease damages their vision. In
this study, the researchers have investigated the association between
AMD and polymorphisms in CFH and LOC387715/HTRA1 in more depth.
They have then used this new information to build a model of AMD risk
that should allow physicians to identify individuals at high risk of
developing neovascular AMD.
What Did the Researchers Do and Find? The researchers catalogued
polymorphisms in CFH and LOC387715/HTRA1 in several hundred people
with and without neovascular AMD. From these data, they identified
three haplotypes (sets of polymorphisms that are inherited as a unit;
everyone inherits two copies of each haplotype, one from each parent)
in CFH that were more common in people with AMD than in those
without and two that were associated with a decreased risk of
developing AMD. In LOC387715/HTRA1 they identified one particularly
detrimental haplotype. Compared to people without this haplotype,
people with one copy of the deleterious haplotype were three times as
likely to develop neovascular AMD; people with two copies were thirty
times as likely to develop AMD. Smoking history also had a large effect
on susceptibility to AMD. The researchers then developed a simple AMD
risk scoring system based on CFH and LOC387715/HTRA1haplotypes and
smoking status. From this, they calculated that people with the lowest
risk scores have a minimal risk of developing AMD whereas about 15%
of people with the highest risk scores are likely to develop AMD.
What Do These Findings Mean? These findings indicate that it is
possible to predict an individual’s risk of developing AMD in old age by
examining a small number of haplotypes and asking about their
smoking status. The model developed by the researchers needs to be
validated in other groups of people and may have to be modified if
other gene variants that affect the risk of AMD are identified. For now,
the results of this research provide physicians with a way to identify
those individuals at the highest genetic risk of developing AMD so that
they can step up their efforts to persuade these people to avoid
smoking. In the future, when effective long-term treatments for AMD
become available, the scoring system could also help doctors decide
which of their elderly patients should be monitored most intensively for
the early signs of AMD so that they can be treated before their vision is
irreversibly damaged.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040355.
  MedlinePlus provides links to information on macular degeneration
and an encyclopedia page on macular degeneration (in English and
Spanish)
  Pages on the US National Institutes of Health NIH SeniorHealth site
provides text and speech information about AMD
  The US National Eye Institute and the UK Royal National Institute of
Blind People also provide information about AMD
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